Analyst Price Targets — CING
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 19, 2025 1:00 am | Boobalan Pachaiyappan | Roth Capital | $11.00 | $3.82 | TheFly | Cingulate price target lowered to $11 from $12 at Roth Capital |
Latest News for CING
Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues to position CTx-1301 toward a potential commercial ADHD launch, with the regulatory focus now centered on manufacturing (CMC) rather than clinical performance.
Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPTO) cleared a key patent application for the firm's “Trimodal, Precision-Time Pulsatile Release Tablet.” This regulatory victory effectively safeguards the proprietary technology behind Cingulate's lead ADHD candidate – CTx-1301 – providing a massive boost to investor confidence as the company prepares for a…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CING.
U.S. House Trading
No House trades found for CING.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.